These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38092611)

  • 1. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Beckabir W; Wobker SE; Damrauer JS; Midkiff B; De la Cruz G; Makarov V; Flick L; Woodcock MG; Grivas P; Bjurlin MA; Harrison MR; Vincent BG; Rose TL; Gupta S; Kim WY; Milowsky MI
    Eur Urol; 2024 Mar; 85(3):242-253. PubMed ID: 38092611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
    Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
    Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
    Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
    PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer.
    Mendoza-Valderrey A; Choe J; Kessler DM; Jimenez G; Li X; Kolker S; Allen W; Linehan JA; Twardowski PW; Ascierto ML
    Cancer Med; 2024 Aug; 13(15):e70088. PubMed ID: 39119802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Kim H; Jeong BC; Hong J; Kwon GY; Kim CK; Park W; Pyo H; Song W; Sung HH; Hong JY; Park SH
    Cancer Res Treat; 2023 Apr; 55(2):636-642. PubMed ID: 36228654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
    Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
    Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Grassauer J; Schmidt J; Cowan A; Gilbert SM; Chakiryan NH
    Eur Urol Oncol; 2024 Feb; 7(1):139-146. PubMed ID: 37453853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
    Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer.
    Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
    Front Immunol; 2022; 13():986359. PubMed ID: 36059550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
    Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
    JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
    Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.